Brief: Celon Pharma Gets Positive Opinion Confirming Reduzek Compliance With Safety Requirements
10/09/2026 13:16
BRIEF-Celon Pharma Gets Positive Opinion Confirming Reduzek Compliance With Safety Requirements Sept 10 (Reuters) - Celon Pharma SA CLNP.WA:
RECEIVES POSITIVE NOTIFIED BODY OPINION FROM TÜV RHEINLAND LGA PRODUCTS CONFIRMING COMPLIANCE OF PRE-FILLED INJECTOR WITH GENERAL SAFETY AND PERFORMANCE REQUIREMENTS
OPINION ENABLES CELON PHARMA TO CONTINUE CELON SEMAGLUTIDE PROJECT REDUZEK DEVELOPMENT AS SCHEDULED
Source text: ID:nEM2qhvsya
Further company coverage: CLNP.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Celon Pharma SA
See all newsBrief: Celon Pharma Projects Recommended For About 29.9 Mln Zlotys Funding By Poland's Medical Research Agency
Brief: Celon Pharma Files Marketing Authorization Applications In EU For Semaglutide Drug Injection Solution
Brief: Celon Pharma Q2 Net Loss At 30.6 Million Zlotys
Brief: Celon Pharma Gets Positive Opinion Confirming Reduzek Compliance With Safety Requirements
Celon Pharma's generic semaglutide drug matches Ozempic in early study, shares jump